This week, I attended the Consumer Genomics Show (more so a “clinical genomics" show). In a session on Next Generation Sequencing led by five industry experts, a recurring observation was that, on the one hand, steady investments in sequencing technology was indeed delivering breathtaking value and driving down sequencing costs – bravo indeed and ...
Despite understandably varied opinions on the US federal government, I think that most of us can agree that U.S. National Institute of Health (NIH) has done remarkable things for the world and life sciences. They are the world driver and biggest supporter of genetic research, they largely funded the $3B Human Genome Project, and ...
The most thoughtful folks in the health care industry acknowledge that the future will be defined by molecular (aka personalized) medicine. Without being infinitely tedious, it will be a matter of measuring your body's instructions (DNA) and your present state (RNA/proteins) and prescribing a course of treatment with the most likely positive outcome and ...
GenomeQuest could have targeted consumers, the largest available market for its technology. When we entered the market in 2004, the consumer wave was a distant vision, not even on the horizon. How did we survive? We targeted the smallest segment we could find: Information Scientists and Biotech Patent Lawyers. Why? My father was a old-school ...
Brad Perriello at MassDevice interviewed me and posted the article in their popular e-newsletter on the medical device industry. You can read the interview here. Brad caught me a little off guard when he asked me what I considered to be the ethical implications of individuals having access to their genomes. In a couple ...